Treace Medical Concepts Reports Q4 Revenue Growth Amid Operational Improvements

Treace Medical Concepts delivered stronger-than-expected financial results in the fourth quarter of 2025, reporting revenue of $21.3 million, a 12% increase compared to $19.0 million in Q4 2024. The growth was driven primarily by expanded distribution of its proprietary gastrointestinal stent products in the U.S. and early international market entry in select European regions. Despite the revenue gain, the company recorded a net loss of $3.7 million for the quarter, a significant improvement from the $5.1 million net loss reported during the same period in 2024, reflecting cost discipline and operational efficiencies. The company’s adjusted EBITDA for Q4 reached $2.9 million, up from $1.2 million in the prior-year quarter, signaling improved underlying profitability. Management attributed this progress to supply chain optimization, reduced manufacturing downtime, and increased salesforce productivity. Treace also announced the successful completion of a pivotal clinical trial for its next-generation esophageal stent, with data expected to be submitted to the FDA for premarket approval in Q2 2026. The stock, trading under the ticker TRAC, saw a 7% intraday surge following the earnings release, supported by investor confidence in the company’s path toward sustained revenue expansion and near-term regulatory milestones. Analysts noted that while Treace remains a small-cap player, its progress in clinical development and commercial execution may position it for increased visibility among specialty medical device investors.